| INTRODUCTION
Prostate cancer (PCa) varies widely among different ethnicities, with African American (AA) men exhibiting an earlier onset of disease and the higher incidence (214.5 per 100 000) and mortality rate (46.3 per 100 000) of any group in the world. 1 In other populations of African descent, there is also a high risk of developing PCa. [2] [3] [4] [5] [6] PCa in the Latino population in general and in the Puerto Rican (PR) population in particular has been rarely described. The high mortality (29.0 per 100 000) from PCa observed among PRs living in the island, when compared to continental US Hispanic (17.8 per 100 000) and non-Hispanic white (19.8 per 100 000) populations has yet to be addressed. 1, 7 The PR population, as many others in the Americas, is highly heterogeneous due to the admixture of Native Americans, Europeans, and West Africans. Interestingly, the island of Puerto Rico has higher tri-hybrid admixture than other Hispanic populations. In 2011, Via and collaborators estimated genetic admixture on the island, reporting 15 .2% Native American, 63.7% European, and 14.4% West African ancestries, respectively among the population. 8 Importantly, some studies have found disparities in the incidence of diseases or response to treatments in the PR population when compared to other Latino groups. [9] [10] [11] West Africa is the major ancestral component of AA men as well as of men of African descent in the Caribbean. [12] [13] [14] It is plausible that genetic susceptibility loci stemming from the West African ancestral (WAA) population may influence the heterogeneity with respect to mortality from PCa in the PR population.
Ricks-Santi and collaborators used Ancestry Informative Markers
(AIMs) [15] [16] [17] to assess the contribution of WAA in risk of PCa in AAs and to detect genetic variants associated with PCa in this population.
Recently, Fernandez et al, 15 correlated SNPs associated with PCa susceptibility in men with mixed ancestry and men with European ancestry (EA) in South Africa. The former had an earlier onset of PCa and also had a higher frequency of metastatic disease. 18 Other studies [19] [20] [21] [22] [23] have analyzed ancestry and SNPs related to PCa, however none has examined PCa disparities in the PR population.
In the present pilot study, we investigated whether WAA was associated with PCa risk and aggressiveness in this genetically heterogeneous population and compared them to AA men. We assessed WAA ancestry in PCa cases and healthy controls; we tested the hypothesis that WAA is correlated with aggressive PCa subsequent to radical prostatectomy (RP) and also performed SNP association tests for 15 GWAS-identified PCa risk related SNPs [24] [25] [26] (Supplemental Table S1 ). To date no study has correlated WAA using AIMs with PCa aggressiveness in a Hispanic-Caribbean understudied population.
| METHODS
This study was performed after approval by the Institutional Review 
| DNA Extraction
The sources of genomic DNA for genotyping were either whole blood from the control subjects or paraffin embedded tumor free seminal vesicle tissue from the cases. DNA extraction from paraffin embedded tissue followed standard published methodologies. 28 Briefly, 5-10 micron shavings of non-tumor seminal vesicle tissue were deparaffinized in octane and methanol, lysed, and treated with proteinase K.
Subsequently, DNA was purified by precipitation with isopropanol and 3-5 μL of glycogen (Sigma, St. Louis, Mo). DNA was washed in 1 mL of 70% ethanol and then set to dry. Dried DNA was dissolved in 25-50 μL of DNA hydration buffer (Qiagen INC. Valencia CA) and stored at −20°C. DNA extraction and purification from blood was done following manufacturer's instructions in Gentra Puregene kit from Qiagen (Qiagen Inc., Valencia, CA).
Quantification of the DNA was done using a NanoDrop 2000 spectrophotometer (Thermo Scientific). DNA quality and integrity was assessed performing a PCR for the housekeeping gene G3PDH
(Glyceraldehyde-3-Phosphate Dehydrogenase).
| Genotyping of SNPs
Sequenom Mass ARRAY™ was used for genotyping 100 unlinked AIMs 29 and SNPs strongly associated with PCa risk in previous GWAS studies. [24] [25] [26] iPLEXTM assays were designed utilizing the Sequenom Assay Design software, allowing for single base extension (SBE) designs used for multiplexing. Multiplex assays were performed to amplify 5-10 ng of genomic DNA by polymerase chain reaction (PCR).
Subsequently, a post-PCR single base extension reaction was The difference in SNPs presence between groups stratified by study site, case/control status, and disease aggressiveness was assessed using the Chi-squared test. The WAA, EA, or NA data were compared between groups using the Wilcoxon rank-sum test.
The study was designed to enroll respectively 300 PR and 200 AA cases with >90% power to detect an association between WAA and PCa aggressiveness, assuming 20% of cases were high grade or stage.
In addition, the study had 86% power to detect a difference in means of 3% (μ1 = 0.82 and μ2 = 0.79) with a sample size of 300 cases and controls in the PR group (as observed in AAs by Robbins et al, 17 assuming that the common standard deviation is 0.100 using a two group t-test with a 0.010 two-sided significance level. We tested for differences in ancestry distributions between cases and controls by fitting logistic regression models with case-control status as the outcome and genetic ancestry as the main co-variate, modeling genetic ancestry as either a continuous or categorical variable.
We also used logistic regression models to test the effect of PCa risk SNPs on PCa in our subjects. The MDACC cohort of AA cases and controls served as a positive control for AIM expression as well as for
SNPs previously shown to be associated with PCa among AA cohorts.
When assessing the statistical significance of the SNPs in association with sites, case/control status, or PCa aggressiveness, the Bonferroni correction method was used to adjust for multiple comparisons. All statistical analyses were conducted using SAS (version 9.3).
| RESULTS
Recruitment of cases from both cohorts reached the stated goal among the MDACC cohort and missed the goal (n = 300) from PR by nine cases (n = 291). Control recruitment from the PR site did not reach the goal of 300 subjects achieving 44% (n = 133) of the target accrual.
Control subject accrual from the MDACC site was successful in matching case recruitment of subjects. 
| Clinico-demographic characteristics of the cohorts
The subject age distribution, serum PSA levels, and body mass index (Table 1) were different among cases and controls from PR and MDACC. PR cases were older, had higher serum PSA levels and lower BMI than MDACC cases. Gleason score and disease severity were higher in cases at MDACC. At both sites the incidence of smoking was higher in cases. Cases from MDACC exhibited a higher incidence of affected first degree relatives than the control group. No such difference was noted for the PR population. The cohort from
Puerto Rico exhibited higher levels of educational achievement (68.6-82% > 12th grade educational level) when compared to the MDACC cohort (44-62.9% > 12th grade educational level).
| Genetic ancestry
Ancestry analyses were performed to assess the differences between MDACC and PR subjects and differences between cases and controls, and between low and high risk PCa at each site. Table 2 summarizes the ancestry data by study site. As expected there was significantly higher WAA among MDACC subjects (median = 77%) as compared to PR | 1121 subjects (median = 17%) (P < 0.0001), while PR subjects had significantly higher levels of both EA and NA than the MDACC cohort.
In Fig. 1 we provide an ancestry distribution plot by disease status, for both sites. The ancestry distribution had a significant difference (P < 0.05) between cases and controls only at the MDACC site, with cases exhibiting significantly lower WAA but higher EA and NA. There was no difference in percent WAA between PR cases and controls.
(Supplemental Table S2A ,B)
We found no significant difference in ancestral proportions between low and high risk cases ( Tables S3,S4 ). In addition when we assessed for an association between serum PSA and WAA, we did not find a significant association in the PR cohort (P = 0.16). However, among the MDACC cohort serum PSA levels were significantly lower among the AA cases with higher WAA (P = 0.03). When we compared the SNPs allele frequencies among the PR and MDACC cohorts we noted significant differences in 11 of 13 (P < 0.0033) after Bonferroni adjustment for multiple comparisons.
| SNPs analysis
(Supplemental Table S5 ).
In the MDACC cohort (n = 409), there were three SNPs that initially exhibited a significant difference in frequencies between cases and controls: rs7824364, rs6983267, and rs7210100 (P < 0.05, Gleason score ≥8 PCa the association was lost after adjustment for multiple comparisons (data not shown).
In the PR cohort, SNP rs7824364, was also significantly different between the cases and controls (P = 0.0001), Table 5 , with cases having a higher percentage (41%) of one or two alleles compared to the controls (19%), respectively. Of note given that rs7824364 was significantly associated with PCa among both cohorts we next examined whether WAA was increased among PR men having one or both of the minor alleles at this locus . The median level of WAA among the PR cohort was 17%. However, among PR having 1-2 minor alleles at the rs7824364 Locus, WAA was increased above the median to 39.3% versus 29.2% (P = 0.034) in PR men with no minor alleles.
SNP rs7210100 was also initially associated with pathologic stage >pT2 (P = 0.04). However, after adjustment for multiple comparisons, this difference did not achieve statistical significance (data not shown).
Multiple logistic regression analysis was performed to determine variables associated with case/control status in the MDACC and PR cohorts separately. The variables considered included the rs7824364 SNP, WAA, age, BMI, PSA, education level, and family history of PCa.
Although in both sites the minor allele frequencies for SNP rs7824364
were significantly different between cases and control after univariate analysis, it was no longer significant in the multivariate model for either site after adjusting for serum PSA levels. In the PR cohort, age remained independently associated with case status as did lower WAA among the MDACC cohort (Supplemental Table S6 ).
| DISCUSSION
Given the higher PCa mortality among both the PR and AA PCa patients and the heterogeneous ancestral background among the PR population we hypothesized that WAA could be related to PCa mortality among PR PCa patients. In this pilot study an increasing percentage of WAA was not directly associated with either the presence or phenotype of PCa among a select population of men undergoing RP. In fact, an enrichment for WAA was found in the healthy control cohort from the MDACC site. This finding has prompted us to study other potential confounders since the AA controls were recruited from community settings in Houston while the cases were AA patients from the MDACC, a tertiary referral center for treatment of cancer. We have previously shown that subjects recruited in the Houston community study exhibited a lower socioeconomic (SES) status in terms of education, insurance, and having a regular physician. 27 Freeman et al 33, directly correlated low SES with lower PCa survival and found that this was eliminated in equal access care settings. 33 evaluating other variables their group found that obesity was a significant predictor of aggressive PCa for the EA population more than the AA cohort. 37 Saturated fat however was associated with aggressive PCa but only in the EA cohort. 38 The effect that SES or environmental factors may have on modifying PCa in our cohorts is currently being studied.
When comparing our study with another that suggested an association of increasing WAA and PCa we noted several differences.
Our study was a case control and case-case design to define if increasing WAA was associated with PCa. Controls were pre-selected based upon a normal DRE and serum PSA <2.5 ng/mL with the median PSA of 0.7-0.8 ng/mL. In contrast, in the longitudinal cohort study by Giri et al. 39 AA men and men with a family history of PCa were included in the study and underwent biopsy using pre-specified criteria over time. They found a significant increasing prediction of PCa among AA men (vs Caucasian) at lower PSA baseline levels. 39 This relationship trended toward AA cohorts with an increasing percent of WAA but did not reach significance. The authors noted that their study was relatively small but raised the possibility of a lower risk cohort among AA men that could be defined using WAA. Given the difference in our two study designs our data does not contradict the findings of Giri et al 39 in raising the possibility that among heterogeneous populations of men of African descent PCa risk or phenotype may differ. In fact in a follow-up study we will test this hypothesis by evaluating a group of AA men at risk for PCa based upon clinical features to determine if WAA (among other factors) is a risk factor for a positive biopsy, aggressive pathology, or affects the relationship between serum PSA levels and a subsequent cancer diagnosis.
Among cases we did not find enrichment for WAA among aggressive RP cases when compared with less aggressive cancers from either cohort of AA or PR men. These data do not support our hypothesis that increasing WAA itself is associated with PCa aggressiveness in the PR population and the mortality disparity noted.
However, we cannot definitively rule out such a relationship since we did not examine endpoints such as disease recurrence or mortality, nor analyzed WAA among a broader population of PCa patients exhibiting the whole spectrum of the disease to determine its impact on metastatic disease or death in the cohorts. To address this limitation we are currently gathering data on a larger cohort of men from both populations along with clinical follow up to assess disease recurrence and mortality and its relationship with genetic ancestry. A second limitation of our study is that we did not reach the target accrual goal for the PR control cohort and our relatively small overall study size. It was encouraging to note however, that the proportions of WAA among men of African proportion noted in the study by Giri et al. 39 among another AA cohort (mean = 0.75). 39 In addition the genetic admixture among PR men reported in our study was virtually identical to that reported by Via et al. 8 In this pilot study, we also wanted to determine in a comparative fashion if there were genetic similarities in alleles associated with PCa or its phenotype among our two cohorts. Of the 15 SNPs in the panel, 9
were in the 8q24 region, an area highly enriched for both African ancestry and PCa risk. | 1125
We noted that three SNP loci trended toward a significant association with PCa, rs7824364 (both cohorts), rs6983267 (MDACC cohort), and rs7210100 (MDACC cohort) (P < 0.05, see Tables 4 and 5 ).
Moreover, in the case only analysis SNP loci rs6983267 among AA men and rs 7210100 among PR men were found to be associated with more aggressive PCa with respect to Gleason score and pathologic stage, respectively (Supplemental Tables S7,S8 ).
SNPs rs7824364, rs6983267, are located in the chromosome 8q24 region known to be enriched among men of African descent (MAD) with PCa. 40, 41 The third (rs7210100) located on chromosome 17q21 was also described by Haiman et al 42 among MAD. This SNP was highly associated with PCa and appeared to be correlated with lower Gleason score and stage PCa. 42 It was interesting that in the PR cohort in this study it trended toward an association with higher pathologic stage. In the above study Haiman et al 42 noted that the risk allele had a frequency of only about 5% among MAD. The frequency among the PR in our study was even lower at 1.4% while among the MDACC cohort of AA it was substantially higher at 7.5%.
A major finding in the current study was that SNP locus (rs7824364) 43 This highlights an important region of ancestry specific racial variation in PCa. We found that among both AA men in the MDACC cohort and the heterogeneous PR population rs7824364 remained significantly associated with PCa with one or both alleles present in 82 and 41% of cases, respectively. Furthermore, we found WAA was significantly increased among PR men having at least one allele (P = 0.034) versus those with none present. This was a novel finding and suggests a link between PCa, WAA, and the PR population that clearly deserves further study.
In summary, this study presents the initial results of evolving data on the possible interactions of ancestry, PCa genetic risk loci, and PCa in a comparative fashion among PR and AA men. We found a PCa associated locus at 8q24 region 2 among both cohorts that was associated with increased WAA among the PR PCa cohort. This extends our knowledge with respect to PCa among the understudied PR population. We did not directly demonstrate an association between WAA and disease severity within the confines of a prostatectomy cohort in either group. Whether increased WAA affects PCa recurrence or mortality is currently under study together with socioeconomic and environmental factors that may influence the onset or progression of the disease. 
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